Aberdeen Group plc Buys 81,094 Shares of Abbott Laboratories $ABT

Aberdeen Group plc raised its stake in Abbott Laboratories (NYSE:ABT) by 4.2% during the 2nd quarter, Holdings Channel reports. The fund owned 2,018,942 shares of the healthcare product maker’s stock after acquiring an additional 81,094 shares during the period. Aberdeen Group plc’s holdings in Abbott Laboratories were worth $272,880,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of ABT. First Fiduciary Investment Counsel Inc. increased its holdings in shares of Abbott Laboratories by 4.0% during the second quarter. First Fiduciary Investment Counsel Inc. now owns 3,926 shares of the healthcare product maker’s stock worth $534,000 after purchasing an additional 150 shares during the period. PDS Planning Inc increased its holdings in shares of Abbott Laboratories by 3.0% during the second quarter. PDS Planning Inc now owns 120,786 shares of the healthcare product maker’s stock worth $16,428,000 after purchasing an additional 3,464 shares during the period. JB Capital LLC increased its holdings in shares of Abbott Laboratories by 19.3% during the second quarter. JB Capital LLC now owns 2,867 shares of the healthcare product maker’s stock worth $390,000 after purchasing an additional 464 shares during the period. Blue Trust Inc. increased its holdings in shares of Abbott Laboratories by 0.7% during the second quarter. Blue Trust Inc. now owns 33,492 shares of the healthcare product maker’s stock worth $4,555,000 after purchasing an additional 236 shares during the period. Finally, Robertson Stephens Wealth Management LLC increased its holdings in shares of Abbott Laboratories by 8.1% during the second quarter. Robertson Stephens Wealth Management LLC now owns 22,676 shares of the healthcare product maker’s stock worth $3,084,000 after purchasing an additional 1,693 shares during the period. 75.18% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on ABT. Benchmark began coverage on shares of Abbott Laboratories in a report on Friday. They set a “buy” rating and a $145.00 target price on the stock. Wells Fargo & Company lowered their target price on shares of Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating on the stock in a report on Friday, July 18th. Leerink Partnrs raised shares of Abbott Laboratories to a “hold” rating in a report on Monday, June 16th. William Blair raised shares of Abbott Laboratories to a “strong-buy” rating in a report on Thursday, July 17th. Finally, Leerink Partners started coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They issued a “market perform” rating and a $143.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $146.17.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of NYSE:ABT opened at $132.30 on Friday. The company’s 50 day simple moving average is $132.54 and its 200 day simple moving average is $131.56. The stock has a market capitalization of $230.26 billion, a price-to-earnings ratio of 16.58, a price-to-earnings-growth ratio of 2.53 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. Abbott Laboratories has a 1 year low of $110.86 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.26. The firm had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company’s revenue was up 7.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, research analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s payout ratio is presently 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.